Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot, Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3

NCT00992771 is registered in ClinicalTrials.gov with University of South Florida as lead sponsor.

NCT NCT00992771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00992771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot, Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
Lead sponsor
University of South Florida
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2009
Completion date
April 30, 2011
Enrollment
20 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

spinocerebellar ataxia type 3